Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BrukerBSP:B2RK34 57 EV-to-EBITDA is 6.71 as of Aug. 31, 2026, which is 66% below its 10-year median of 19.46. GuruFocus rates BSP:B2RK34 with a GF Score™ of 57/100 and a GF Value™ of R$30.28 (Fairly Valued). The stock has 11 warning signs investors should review. Among 520 Medical Devices & Instruments companies, Bruker ranks worse than 75.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bruker's enterprise value is R$13,349 Mil.
Bruker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was R$1,989 Mil. Therefore, Bruker's EV-to-EBITDA for today is 6.71.
The historical rank and industry rank for Bruker's EV-to-EBITDA or its related term are showing as below:
BSP:B2RK34'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.4 Med: 19.46 Max: 35.23
Current: 27.39
During the past 13 years, the highest EV-to-EBITDA of Bruker was 35.23. The lowest was 13.40. And the median was 19.46.
BSP:B2RK34's EV-to-EBITDA is ranked worse than 75.77% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 14.66
vs BSP:B2RK34: 27.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-31), Bruker's stock price is R$30.50.
Bruker's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was R$-3.649. Therefore, Bruker's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bruker's share price for today is R$30.50.
Bruker's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-3.649.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bruker's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:B2RK34 vs PODD, BIO, GKOS: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Bruker's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bruker EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bruker's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bruker's EV-to-EBITDA falls into.
Bruker's current Enterprise Value is R$13,349 Mil.
Bruker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1,989 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bruker (BSP:B2RK34) has a EV-to-EBITDA of 6.71 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bruker. This is 66% below median its historical median of 19.46. Over the past decade, Bruker's EV-to-EBITDA has ranged from 13.40 to 35.23. According to the industry distribution chart, Bruker ranks #394 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 75.8%.
Is Bruker's EV-to-EBITDA too high?
Bruker's current EV-to-EBITDA of 6.71 is 66% below median its 10-year median of 19.46. Over the past 10 years, this metric has ranged from a low of 13.40 to a high of 35.23. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.66. Bruker's value of 6.71 is 54.2% below this industry median. Based on the distribution chart, Bruker ranks #394 out of 520 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bruker has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bruker's EV-to-EBITDA compare to PODD and BIO?
According to the Medical Devices & Instruments industry distribution chart, Bruker ranks #394 out of 520 companies for EV-to-EBITDA. This places Bruker in the lower half of its industry. The industry median EV-to-EBITDA is 14.66. Bruker's value of 6.71 is 54.2% below this benchmark. Historically, Bruker's own EV-to-EBITDA has ranged from 13.40 to 35.23 over the past decade. While the company's 10-year median is 19.46 vs. the industry median of 14.66, Bruker has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.66, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bruker's current EV-to-EBITDA of 6.71 is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bruker. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bruker's current EV-to-EBITDA is 6.71, which is 66% below median its own 10-year median of 19.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bruker stock overvalued right now?
Based on GuruFocus' analysis, Bruker (BSP:B2RK34) is currently considered Fairly Valued. The stock's GF Value™ is R$30.28, compared to a current price of R$30.50 — trading 0.7% above its estimated fair value. The current EV-to-EBITDA is 6.71, which is 66% below median its 10-year median of 19.46 and 54.2% below the Medical Devices & Instruments industry median of 14.66. Bruker's overall GF Score™ is 57/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bruker (BSP:B2RK34), the current EV-to-EBITDA is 6.71 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bruker (BSP:B2RK34) Overvalued in 2026?
Based on GuruFocus' analysis, Bruker stock appears to be overvalued.
The current stock price of R$30.50 is trading 0.7% above its estimated GF Value™ of R$30.28.
GuruFocus considers Bruker to be Fairly Valued.
Key valuation signals for BSP:B2RK34:
EV-to-EBITDA: 6.71 (66% below median its 10-year median of 19.46)
GF Value™: R$30.28 vs. price of R$30.50 (0.7% above fair value)
Industry Position: 54.2% below the Medical Devices & Instruments median (#394 of 520)
No single metric tells the full story. See the BSP:B2RK34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
57GF Score
Get the complete analysis for BSP:B2RK34
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B2RK34 has been successfully added to your 
